Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05594602 · ClinicalTrials.gov registry record · Phase 1
Drug-Drug Interaction Study Between EDP-235, Itraconazole, Carbamazepine and Quinidine in Healthy Subjects.
A Phase 1 study, sponsored by Enanta Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 36
- Enrollment target
NCT05594602 is a Phase 1 study that has completed, run by Enanta Pharmaceuticals. The registered enrollment target is 36 participants.
The verdict
NCT05594602, a Phase 1 study, has completed, sponsored by Enanta Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 36 participants
- Enrollment target
Study Summary
A Drug-Drug Interaction study to assess the effects of itraconazole, carbamazepine and quinidine on the Pharmacokinetics and Safety of EDP-235.
Interventions
- DRUG Itraconazole
- DRUG Carbamazepine
- DRUG EDP-235
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 36 participants |
| Start Date | 2022-10-06 |
| Est. Completion | 2022-12-30 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05594602
The ClinicalTrials.gov registry entry for NCT05594602 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 36 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Enanta Pharmaceuticals, which has 36 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Itraconazole is the first listed.
NCT05594602 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05594602 about?
NCT05594602 is a clinical study titled "Drug-Drug Interaction Study Between EDP-235, Itraconazole, Carbamazepine and Quinidine in Healthy Subjects.". A Drug-Drug Interaction study to assess the effects of itraconazole, carbamazepine and quinidine on the Pharmacokinetics and Safety of EDP-235.
What is the current status of trial NCT05594602?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 36 participants. The study started on 2022-10-06. Estimated completion is 2022-12-30.
What interventions are being tested in trial NCT05594602?
The interventions under investigation include: Itraconazole (DRUG), Carbamazepine (DRUG), EDP-235 (DRUG).
Who is sponsoring clinical trial NCT05594602?
This trial is sponsored by Enanta Pharmaceuticals, which has 36 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.